| Drug Name: | Famotidine (76824-35-6) |
|---|---|
| PubChem ID: | 119057364 |
| SMILES: | C1=C(N=C(S1)N=C(N)N)CSCC[13C](=NS(=O)(=O)N)N |
| InchiKey: | XUFQPHANEAPEMJ-PTQBSOBMSA-N |
| Therapeutic Category: | Anti-Ulcer Agents, Gastrointestinal Agents, Histamine Agents, Histamine Antagonists, Histamine H2 Antagonists, Neurotransmitter Agents |
| Molecular Weight (dalton) | : | 338.448 |
| LogP | : | -0.768 |
| Ring Count | : | 1 |
| Hydrogen Bond Acceptor Count | : | 6 |
| Hydrogen Bond Donor Count | : | 4 |
| Total Polar Surface Area | : | 175.83 |
This panel provides information on interacting drugs and their ADRs along with references
| Interacting drug | Toxicity | Interaction Type | Mechanism | Reference |
|---|---|---|---|---|
| Dipyridamole (58-32-2) | Reduce The Bioavailability Of Dipyridamole | Antagonistic | FAmotidine raises the stomach pH significantly would be likely to reduce the dissolution and absorption of dipyridamole | pH-related changes in the absorption of dipyridamole in the elderly |
This panel provides drug-protein interaction and their ADRs along with references
| Toxicity | Interacting Protein | Mechanism | Reference |
|---|---|---|---|
| Bone Marrow Failure | Granulocyte colony-stimulating factor receptor (Q99062) | The interleukin 3-(IL-3) and granulocyte macrophage colony-stimulating factor-(GM-CSF) dependent growth was affected; a combination of growth factors (IL-3@ GM-CSF@ and G-CSF@ the granulocyte colony-stimulating factor) resulted in a less reduced growth@which is compatible with drug-induced bone marrow failure [ ADR Type 5 ] | The growth capacity of hematopoietic progenitor cells in severe neutropenia induced by famotidine |
| Bone Marrow Failure | Granulocyte-macrophage colony-stimulating factor (P04141) | The interleukin 3-(IL-3) and granulocyte macrophage colony-stimulating factor-(GM-CSF) dependent growth was affected; a combination of growth factors (IL-3, GM-CSF, and G-CSF, the granulocyte colony-stimulating factor) resulted in a less reduced growth,which compatible with drug-induced bone marrow failure. [ ADR Type 5 ] | The growth capacity of hematopoietic progenitor cells in severe neutropenia induced by famotidine |
| Bone Marrow Failure | Interleukin-3 (P08700) | The interleukin 3-(IL-3) and granulocyte macrophage colony-stimulating factor-(GM-CSF) dependent growth was affected; a combination of growth factors (IL-3@ GM-CSF@ and G-CSF@ the granulocyte colony-stimulating factor) resulted in a less reduced growth@which compatible with drug-induced bone marrow failure. [ ADR Type 5 ] | The growth capacity of hematopoietic progenitor cells in severe neutropenia induced by famotidine |
This panel provides drug-food interactions and their ADRs along with references
| Food | Toxicity | Reference |
|---|
This panel provides information on metabolites and their ADRs along with references
| Metabolite | Toxicity | Place of Metabolism | Mechanism | Reference |
|---|
This panel provides information on drug category